AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10594270 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 100
Study 10594270 — intervention group
Group type: COMPARATOR
Intervention: Open splenectomy (OS)
Number of subjects: 100
Study 7567290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (7.5 mg/kg orally twice daily for 14 days)
Number of subjects: 124
Study 7567290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 to 70 mg/kg im once daily for 5 days)
Number of subjects: 124
Study 7567290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (50 to 70 mg/kg im every 8 hours for 7 days)
Number of subjects: 124
Study 2026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation period
Number of subjects: 6
Study 2026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleration suggestion period
Number of subjects: 6
Study 2026339 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 6
Study 6930476 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseous recontouring
Number of subjects: 12
Study 6930476 — intervention group
Group type: COMPARATOR
Intervention: Flap curettage
Number of subjects: 12
Study 31594202 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat treatment applied to trigger points
Number of subjects: 40
Study 31594202 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study 31585944 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 800 mg four times daily for five days (total 16 g)
Number of subjects: 433
Study 31585944 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 1000 mg three times daily for 10 days (total 30 g)
Number of subjects: 433
Study 28111386 — intervention group
Group type: EXPERIMENTAL
Intervention: group‐AE (1.0 vol% 3‐acryloxypropyltrimethoxysilane+experimental resin)
Number of subjects: 10
Study 28111386 — intervention group
Group type: EXPERIMENTAL
Intervention: group‐BM (1.0 vol% 3‐acryloxypropyltrimethoxysilane+0.5 vol% bis‐(1,2‐triethoxysilyl)ethane+Multilink® Speed)
Number of subjects: 10
Study 25829811 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg before PCI and for 5 days after PCI
Number of subjects: 67
Study 25829811 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 mg daily after PCI)
Number of subjects: 67
Study 25829811 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 67
Study 25829811 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 23498778 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol AM
Number of subjects: 40
Study 23498778 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol AS
Number of subjects: 40
Study 23498778 — intervention group
Group type: COMPARATOR
Intervention: Epoprostenol GM
Number of subjects: 40
Study 23498778 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 40
Study 21190035 — intervention group
Group type: EXPERIMENTAL
Intervention: 120% of VO₂max (120%(Wmax))
Number of subjects: 14
Study 21190035 — intervention group
Group type: COMPARATOR
Intervention: 80% of the ventilatory threshold (80%(VT))
Number of subjects: 14
Study 19689545 — intervention group
Group type: EXPERIMENTAL
Intervention: McMonnies Dry Eye Index
Number of subjects: 70
Study 19689545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Comfort Index (OCI)
Number of subjects: 70
Study 16463053 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride (calcium channel blocker), starting 3 days before SWL and continued for 4 weeks after the procedure
Number of subjects: 70
Study 16463053 — intervention group
Group type: COMPARATOR
Intervention: Enforced fluid intake
Number of subjects: 70
Study 16463053 — intervention group
Group type: COMPARATOR
Intervention: No specific medication (control group)
Number of subjects: 70
Study 16463053 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride
Number of subjects: 70
Study 16463053 — intervention group
Group type: COMPARATOR
Intervention: High fluid intake
Number of subjects: 70
Study 15001941 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (20-40 microg intranasal) with conditioning alarm therapy
Number of subjects: 207
Study 15001941 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray with conditioning alarm therapy
Number of subjects: 207
Study 11318059 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated drawing
Number of subjects: 0
Study 9503347 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including enlistment of a district advocate, meeting with teachers, using incentives, direct contact with parents, keeping rosters of consent forms, and tailoring strategies for subpopulations.
Number of subjects: 1698
Study 9503347 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment process at four levels: district, school, classroom, and individual.
Number of subjects: 1698
Study 9503347 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of differences between participants and nonparticipants.
Number of subjects: 1698
Study 7896541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 14 mg/m2 daily and 5-fluorouracil 700 mg/m2 daily for 5 days plus alpha-interferon 1 x 10(6) units/m2 daily for five days (phase I)
Number of subjects: 23
Study 7896541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 17 mg/m2/day, 5-fluorouracil 700 mg/m2/day and alpha-interferon 3 x 10(6) units/m2/day (phase II)
Number of subjects: 23
Study 3309298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 141
Study 3309298 — intervention group
Group type: COMPARATOR
Intervention: Diamorphine
Number of subjects: 141
Study 31232898 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrating CCRT
Number of subjects: 150
Study 31232898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontitrating CCRT
Number of subjects: 150
Study 31232898 — intervention group
Group type: COMPARATOR
Intervention: No CCRT
Number of subjects: 150
Study 28194093 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g whey protein + 2 g amylopectin-chromium complex (WPACr)
Number of subjects: 10
Study 28194093 — intervention group
Group type: COMPARATOR
Intervention: 6 g whey protein (WP)
Number of subjects: 10
Study 28194093 — intervention group
Group type: COMPARATOR
Intervention: Comparison of WPACr and WP
Number of subjects: 10
Study 25242569 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-μg transdermal estradiol patch
Number of subjects: 40
Study 25242569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24103853 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LTPP)
Number of subjects: 272
Study 24103853 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine treatment
Number of subjects: 272
Study 24103853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (LTPP + Fluoxetine)
Number of subjects: 272
Study 20729000 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine Vasopressin nasal spray (20 IU)
Number of subjects: 41
Study 20729000 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 41
Study 18482348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tougher and more adhesive food
Number of subjects: 9
Study 18482348 — intervention group
Group type: COMPARATOR
Intervention: Other food
Number of subjects: 9
Study 17175311 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 x 10 g IVIG
Number of subjects: 50
Study 17175311 — intervention group
Group type: COMPARATOR
Intervention: 7 x 10 g IV albumin
Number of subjects: 50
Study 15041604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA; 0.125% ropivacaine plus sufentanil 1 microg/mL at a base rate of 12 mL/h and bolus application of 5 mL/15 min)
Number of subjects: 54
Study 15041604 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient-controlled IV analgesia (PCIA; morphine 3 mg/15 min)
Number of subjects: 54
Study 11461124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential antibiotic therapy (switch therapy)
Number of subjects: 0
Study 9426760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg twice daily
Number of subjects: 1120
Study 9426760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 1120
Study 9426760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg three times daily
Number of subjects: 1120
Study 9426760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg and 2 mg
Number of subjects: 1120
Study 9426760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study 8356971 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye prophylaxis
Number of subjects: 630
Study 3688076 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief support team's protocol of care
Number of subjects: 78
Study 3688076 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care (Control)
Number of subjects: 78
Study 29620994 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of FOLFOX
Number of subjects: 3759
Study 29620994 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of FOLFOX
Number of subjects: 3759
Study 29620994 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of CAPOX
Number of subjects: 3759
Study 29620994 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of CAPOX
Number of subjects: 3759
Study 29620994 — intervention group
Group type: COMPARATOR
Intervention: 6 months of treatment
Number of subjects: 3759
Study 27283779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (lower doses: 100/50/0 mg)
Number of subjects: 0
Study 27283779 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (lower doses: 5/2.5/0 mg)
Number of subjects: 0
Study 27283779 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dose reduction (both treatments)
Number of subjects: 0
Study 24974051 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 200 mg
Number of subjects: 124
Study 24974051 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 400 mg
Number of subjects: 124
Study 24974051 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 1400 mg
Number of subjects: 124
Study 24974051 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-201 (all doses)
Number of subjects: 124
Study 22091929 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of receiving test results either face-to-face or by letter
Number of subjects: 198
Study 22091929 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation for DNA test result disclosure
Number of subjects: 198
Study 20649630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 3118
Study 20649630 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (up to 6 mg/day)
Number of subjects: 3118
Study 20649630 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 3118
Study 20649630 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 3118
Study 18759658 — intervention group
Group type: EXPERIMENTAL
Intervention: CR60 compressor
Number of subjects: 10
Study 18759658 — intervention group
Group type: COMPARATOR
Intervention: PortaNeb (PN) compressor
Number of subjects: 10
Study 15948443 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina ceramic/alumina ceramic bearing
Number of subjects: 495
Study 15948443 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium-on-polyethylene bearing
Number of subjects: 495
Study 15948443 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina liner with thin metal backing
Number of subjects: 495
Study 15228253 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAS3 (sulfadoxine-pyrimethamine + artesunate for 3 days)
Number of subjects: 420
Study 15228253 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAS1 (sulfadoxine-pyrimethamine + artesunate for 1 day)
Number of subjects: 420
Study 15228253 — intervention group
Group type: COMPARATOR
Intervention: SP (sulfadoxine-pyrimethamine alone)
Number of subjects: 420
Study 11176977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose external beam irradiation at a dose of 14 Gy in 7 fractions of 2 Gy
Number of subjects: 83
Study 11176977 — intervention group
Group type: COMPARATOR
Intervention: Sham radiation (observation group)
Number of subjects: 83
Study 9646651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 80
Study 9646651 — intervention group
Group type: COMPARATOR
Intervention: Halothane and nitrous oxide
Number of subjects: 80
Study 7875272 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 125 micrograms carbachol
Number of subjects: 9
Study 7875272 — intervention group
Group type: COMPARATOR
Intervention: Inflation of pneumatic trousers
Number of subjects: 9
Study 2894181 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 0
Study 2894181 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 2894181 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31833919 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based continuing care bundle
Number of subjects: 124
Study 31905341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily dose)
Number of subjects: 520
Study 31905341 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (no aspirin)
Number of subjects: 520
Study 29432808 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxegol 25 mg once daily
Number of subjects: 24
Study 29432808 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 26911949 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily orally for at least 15 days
Number of subjects: 198
Study 26911949 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 198
Study 25695260 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic recruitment strategy
Number of subjects: 186
Study 25695260 — intervention group
Group type: EXPERIMENTAL
Intervention: Informatics recruitment strategy
Number of subjects: 186
Study 25695260 — intervention group
Group type: EXPERIMENTAL
Intervention: Community recruitment strategy
Number of subjects: 186
Study 25695260 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study retention
Number of subjects: 186
Study 25695260 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive refusal rates
Number of subjects: 186
Study 24094795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 10
Study 24094795 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 10
Study 24094795 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 10
Study 20730091 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal serogroup C conjugate vaccine (MenCC) administered at 14 months of age and catch-up immunization for ages 14 months to 18 years.
Number of subjects: 14925
Study 20730091 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal serogroup C conjugate vaccine (MenCC) administered above 5 years of age.
Number of subjects: 14925
Study 20730091 — intervention group
Group type: COMPARATOR
Intervention: Natural immunity (non-immunized adults).
Number of subjects: 14925
Study 20730091 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up immunization (MenCC) in children below 14 months of age.
Number of subjects: 14925
Study 20730091 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up immunization (MenCC) in adolescents.
Number of subjects: 14925
Study 18787989 — intervention group
Group type: EXPERIMENTAL
Intervention: Coma Recovery Scale-Revised (CRS-R)
Number of subjects: 77
Study 18787989 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Coma Scale (GCS)
Number of subjects: 77
Study 18787989 — intervention group
Group type: COMPARATOR
Intervention: Full Outline of UnResponsiveness scale (FOUR)
Number of subjects: 77
Study 18787989 — intervention group
Group type: COMPARATOR
Intervention: Wessex Head Injury Matrix (WHIM)
Number of subjects: 77
Study 16600998 — intervention group
Group type: EXPERIMENTAL
Intervention: Men during 90 min bicycle exercise at 60% VO2peak
Number of subjects: 0
Study 16600998 — intervention group
Group type: EXPERIMENTAL
Intervention: Women during 90 min bicycle exercise at 60% VO2peak
Number of subjects: 0
Study 16600998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of type 1 muscle fibres in women
Number of subjects: 0
Study 16600998 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher capillarization in women
Number of subjects: 0
Study 12581006 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 235
Study 12581006 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 235
Study 10807465 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) and subsequent immunoglobulin G (IgG) substitution
Number of subjects: 18
Study 10807465 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (Control group)
Number of subjects: 18
Study 8830979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline under fasting conditions
Number of subjects: 12
Study 8830979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline under fed conditions
Number of subjects: 12
Study 8830979 — intervention group
Group type: COMPARATOR
Intervention: Both fasting and fed conditions
Number of subjects: 12
Study 8830979 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 12
Study 1591948 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg by mouth 4 times a day)
Number of subjects: 228
Study 1591948 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO (500 mg by mouth 4 times a day)
Number of subjects: 228
Study 1591948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 228
Study 30866914 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture (EA) consisting of needling on 6 unilateral acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) with electronic stimulation
Number of subjects: 60
Study 30866914 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (EA) using a non‐penetrating Park sham device and fake electronic stimulation on the same acupoints
Number of subjects: 60
Study 27787890 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2015
Number of subjects: 531
Study 27787890 — intervention group
Group type: COMPARATOR
Intervention: ETN (Enbrel®)
Number of subjects: 531
Study 27787890 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching treatments
Number of subjects: 531
Study 27173469 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208 (100 mg b.i.d. for 29-33 days)
Number of subjects: 20
Study 24815101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 162
Study 24815101 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin‐only pills (POPs)
Number of subjects: 162
Study 24815101 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper‐releasing intrauterine devices (IUDs)
Number of subjects: 162
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle-to-pulmonary artery shunt
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Norwood right ventricular fractional area change
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomy other than hypoplastic left heart syndrome
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructed pulmonary venous return
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller ascending aorta
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic syndrome
Number of subjects: 549
Study 22341427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower gestational age
Number of subjects: 549
Study 22341427 — intervention group
Group type: COMPARATOR
Intervention: Shunt type
Number of subjects: 549
Study 20655474 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using WHOQoL-Bref
Number of subjects: 81
Study 20655474 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer-related factors (emotional overinvolvement and burden of care)
Number of subjects: 81
Study 17416906 — intervention group
Group type: EXPERIMENTAL
Intervention: GR79236X 4 microg kg‐1
Number of subjects: 79
Study 17416906 — intervention group
Group type: EXPERIMENTAL
Intervention: GR79236X 10 microg kg‐1
Number of subjects: 79
Study 17416906 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg
Number of subjects: 79
Study 17416906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 16281834 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacine (0.5 g) 90‐120 min before TUR
Number of subjects: 120
Study 16281834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacine (0.4 g) 30‐60 min before TUR
Number of subjects: 120
Study 16281834 — intervention group
Group type: COMPARATOR
Intervention: Routine antibiotic prophylaxis (control)
Number of subjects: 120
Study 12217104 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face (FTF)
Number of subjects: 24
Study 12217104 — intervention group
Group type: COMPARATOR
Intervention: Videoconferencing
Number of subjects: 24
Study 10461844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime administered intravenously 10 min before surgery
Number of subjects: 59
Study 10461844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cefuroxime)
Number of subjects: 59
Study 8594657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobenzarit disodium (CCA) in combination with sodium aurothiomalate and D-penicillamine (group-A)
Number of subjects: 157